-
Mashup Score: 3Efficacy and Safety of Tofacitinib in Anti–Melanoma... : JCR: Journal of Clinical Rheumatology - 5 month(s) ago
were treated with tofacitinib and followed up. Clinical and laboratory data of these patients were recorded between January 2019 and June 2022. SPSS was used for all statistical analyses. Results The mean age of patients with MDA5+DM was 45 ± 12.4 years, and the median disease duration was 6.5 months (range, 3–13 months). The mean dosage of glucocorticoids was 34.7 ± 20.9 mg/d at the initiation of tofacitinib therapy. Overall, 47 patients were followed up for a mean duration of 7.8 ± 6.2 months. We found that the clinical symptoms of 28 patients (59.6%) were improved, but 1 patient (2.1%) died because of severe infection. Moreover, complications occurred in 25 patients (53.2%), among whom 19 patients had infections. Older age and C-reactive protein levels close to the upper value in reference range at the initial treatment were found to be the potential risk factors of infection. Furthermore, patients with cutaneous ulcers were found to have a lower risk of infection. Conclusion Tofaci
Source: journals.lww.comCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 0
DESTIN, Fla. — Dermatomyositis and tinea are just two of many dermatologic complications that may resemble rheumatologic conditions, according to a presenter at the 2023 Congress of Clinical Rheumatology-East.
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 3Pneumomediastinum and Subcutaneous Facial Emphysema in Antimelanoma Differentiation-Associated Gene 5 Antibody–Positive Dermatomyositis - 12 month(s) ago
Pneumomediastinum is not a rare complication of antimelanoma differentiation-associated gene 5 (anti-MDA5)–positive dermatomyositis (DM)-associated interstitial lung disease (ILD). Here, we reported a rare case of subcutaneous facial and posterior pharyngeal emphysema due to pneumomediastinum in anti-MDA5-positive DM. A 48-year-old woman presented with progressively increasing right cheek…
Source: The Journal of RheumatologyCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 9
Objective Interstitial lung disease (ILD) is a common extramuscular complication contributing to significant morbidity and mortality in patients with dermatomyositis (DM) who are positive for antimelanoma differentiation–associated gene 5 antibody (anti-MDA5+). We conducted this study to investigate the association of anti-Ro52 antibodies with clinical characteristics and prognosis in patients…
Source: The Journal of RheumatologyCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 1
This cohort study evaluates the incidence of dermatomyositis and its trend over time in the US Department of Veterans Affairs health care system.
Source: jamanetwork.comCategories: Dermatology, Latest HeadlinesTweet
-
Mashup Score: 0Improvement in Dermatomyositis Observed in Patients Given Intravenous Immune Globulin - 1 year(s) ago
Researchers evaluated the use of IVIG for patients with the rare autoimmune disorder dermatomyositis.
Source: HCPLive®Categories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Investigational Cannabinoid Receptor Agonist Proves Safe and Effective in Amyopathic Dermatomyositis - Practical Dermatology - 2 year(s) ago
More than 40 percent of the patients taking lenabasum demonstrated significant improvements.
Source: Practical DermatologyCategories: Dermatology, Latest HeadlinesTweet
-
Mashup Score: 0
This cohort study evaluates the incidence of dermatomyositis and its trend over time in the US Department of Veterans Affairs health care system.
Source: jamanetwork.comCategories: Dermatology, Latest HeadlinesTweet
-
Mashup Score: 3
Objective. The calcineurin inhibitor tacrolimus has been approved in Japan for the treatment of interstitial pneumonia (IP) in patients with polymyositis (PM) and dermatomyositis (DM). Postmarketing surveillance was initiated to examine long-term outcomes of immunosuppressive regimens containing tacrolimus in real-world settings. Methods. Observational, prospective, postmarketing surveillance is…
Source: The Journal of RheumatologyCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 0
Guiding patients with juvenile dermatomyositis from pediatric to adult care is essential to minimize comorbidities and complications, according to data presented at EULAR 2022 Congress.“A 4-year-old is very different than a 16-year-old,” Liza McCann, MD, of the Alder Hey Children’s National Health Service Foundation Trust, in the United Kingdom, said in her presentation.
Source: www.healio.comCategories: General Medicine News, Latest HeadlinesTweet-
Guiding patients with juvenile #dermatomyositis from pediatric to adult care is essential to minimize comorbidities and complications #EULAR2022 #Rheumatology https://t.co/t6BRlvWfnT
-
Efficacy and safety of tofacitinib for the treatment of anti-MDA5 antibody-positive #Dermatomyositis https://t.co/D5R6QATW1f #Rheumtwitter #Myositis